What were the key takeaways from PolyPid’s earnings call?

Did PolyPid beat or miss consensus estimates last quarter?

What were the key takeaways from PolyPid's earnings call?

What is the market's earnings forecast for PolyPid next quarter?

What is PolyPid's gross profit margin?

What guidance did PolyPid's management provide for the next earnings period?

What is the revenue and EPS growth rate for PolyPid year over year?

What does PolyPid do and what are its main business segments?

- **Regulatory Momentum**: FDA supports rolling NDA submission for D-PLEX100, with initial label targeting colorectal surgery. 
- **Commercial Progress**: Advanced partnership discussions with hospital-based experts; 2026 expected to finalize agreements. 
- **Financial Stability**: $12.9M cash on hand, with $3.7M from warrant exercises, funding operations into H2 2026. 
- **Innovation Expansion**: Kynatrix platform expands to systemic therapies (e.g., GLP-1), complementing D-PLEX100's localized delivery. 
- **Growth Catalysts**: 2026 poised for regulatory approval, commercial launch, and pipeline expansion into metabolic disease.

**【CEO Summary Section】**
- Completed SHIELD II Phase III trial in 2025 with D-PLEX100 meeting primary and secondary endpoints, showing significant reduction in surgical site infections (SSIs). 
- Received FDA feedback supporting rolling NDA submission for D-PLEX100, with initial submission expected by end of Q1 2026. 
- Advanced U.S. partnership discussions with hospital-based commercialization experts, reflecting D-PLEX100's clinical profile and unmet need in colorectal surgery. 
- Appointed Brooke Story as Board Chairman, leveraging her medical technology expertise for commercialization strategy. 
- 2026 outlook: transformative year with regulatory, partnership, and commercial readiness milestones.

**【COO Commercial Update】**
- Refreshed brand to reflect transition from R&D to commercialization, emphasizing precision and reliability. 
- Introduced Kynatrix platform, expanding beyond PLEX to systemic applications (e.g., GLP-1 Receptor Agonist program). 
- D-PLEX100 remains near-term focus, with potential label expansion to broader abdominal surgeries post-approval. 
- Partner discussions include experienced players for hospital-based commercialization and prior authorization processes. 
- GLP-1 program targeting 60-day sustained release; preclinical data expected mid-2026 to support partner engagement.

**【CFO Financial Commentary】**
- Q4 2025: R&D expenses $6.2M (down 11% YoY), G&A $1.8M (up 80% YoY), marketing $0.6M (up 200% YoY). 
- FY2025 net loss $34.2M, driven by SHIELD II trial completion and commercial prep. 
- Cash position $12.9M as of Dec 31, 2025, with $3.7M from warrant exercises post-quarter. 
- Funds sufficient for operations into H2 2026, supporting NDA submission and partnership activities.

**【Q&A Highlights】**
- **Label Scope**: FDA supports initial label for colorectal surgery, with potential expansion to broader abdominal procedures. 
- **Partnership Factors**: Partner must have hospital-based reach and surgical suite presence; discussions in advanced stages. 
- **Commercial Readiness**: Pre-launch activities include formulary access, P&T committee engagement, and pilot studies. 
- **GLP-1 Strategy**: Partnering at preclinical stage to leverage D-PLEX100's validated platform for sustained release. 
- **Kynatrix vs PLEX**: Kynatrix expands to systemic delivery (e.g., peptides, STING agonists), while PLEX focuses on localized antibiotics.

PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript

- **FDA Milestone Confidence**: Pre-NDA meeting in December to secure 2026 submission, with $18.8M cash runway.
- **Commercial Momentum**: 80% hospital formulary uptake and 60% surgeon utilization rate from market study.
- **Financial Strength**: Reduced debt to $2.4M, improved net loss to $7.5M, and strategic U.S. manufacturing expansion considerations.

**【CEO Summary Section】**
- Scheduled pre-NDA meeting with FDA in early December to align on data package format and requirements for NDA submission in early 2026.
- Successful GMP inspection by Israeli Ministry of Health, marking fourth consecutive successful inspection and readiness for European market.
- Completed U.S. market access study showing 80% likelihood of hospitals adding D-PLEX100 to formulary and 60% expected utilization rate among surgeons.
- Advanced discussions with U.S. partners leveraging Fast Track and Breakthrough Therapy designations.

**【CFO Financial Commentary】**
- R&D expenses decreased to $5.3M (down from $6.2M Q2 2025) due to Phase III trial completion.
- Net loss improved to $7.5M for Q3, with $18.8M cash balance supporting operations into 2026.
- Debt reduced to $2.4M from $6.5M, reflecting financial discipline.

**【Q&A Highlights】**
- CEO expresses confidence in FDA inspection readiness, citing experienced team and ongoing GMP compliance efforts.
- Potential premium pricing if NTAP designation secured, driven by strong surgeon and hospital interest.
- Exploration of U.S. manufacturing expansion to meet demand and align with local production trends.

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

- **Breakthrough SSI Prevention**: D-PLEX100 reduces SSIs by 58% with no deep infections, positioning for FDA NDA in Q1 2026.
- **GLP-1 Innovation**: 60-day no-burst therapy addresses metabolic disease unmet needs, with preclinical data expected soon.
- **Financial Strength**: $29.5M cash runway supports operations into 2026, with strategic partnerships to fund launch.
- **Strategic Leadership**: New CMO accelerates regulatory and commercial prep, while GLP-1 program expands therapeutic portfolio.

**【CEO Summary Section】**
- **Phase III SHIELD II Trial Success**: D-PLEX100 achieved a 38% reduction in surgical site infections (SSI) with p < 0.005, 58% SSI rate reduction, and 62% lower ASEPSIS severity scores. No deep SSIs in the treatment arm vs. 5 in control. Safety profile showed no serious adverse events difference.
- **GLP-1 Program Expansion**: Developing a 60-day no-burst GLP-1 receptor agonist for metabolic diseases, with preclinical studies underway and potential collaborations.
- **Leadership Strengthening**: Dr. Nurit Tweezer-Zaks appointed as CMO, leveraging her medical and business expertise for regulatory and commercial prep.
- **Financial Resilience**: $29.5M cash runway (June 2025) via warrant exercise, supporting operations into 2026.

**【CFO Financial Commentary】**
- **Cash Position**: $17.4M cash + $12M short-term deposits = $29.5M total (June 2025), up from $15.6M in Q4 2024.
- **R&D Expenses**: $6.2M (Q2 2025) vs. $4.8M YoY, driven by SHIELD II trial completion.
- **G&A Expenses**: $2.5M (Q2 2025) vs. $1.1M YoY, due to PSU vesting costs.
- **Net Loss**: $10M (Q2 2025) vs. $6.3M YoY, reflecting increased R&D and G&A.

**【Q&A Highlights】**
- **NDA Filing Timeline**: Pre-NDA meeting with FDA by end-2025, NDA submission Q1 2026, MAA Europe shortly after.
- **GLP-1 Program Progress**: Preclinical studies to validate PK and safety, targeting clinical collaboration with a major player.
- **Advance Pharma Partnership**: Active discussions on milestones, with prelaunch activities commencing in Europe.
- **Balance Sheet Strategy**: Reliance on partner payments and collaborations to fund launch, exploring nondilutive financing options.

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

- **Trial Milestone Achieved**: SHIELD 2 Phase 3 trial concluded early with 800 patients; top-line data expected June 2025.
- **Regulatory Timeline**: NDA submission in Q1 2026 with Fast Track; European MAA to follow.
- **Financial Strength**: $15M financing extends runway to Q3 2025; $27M potential from warrant exercise post-positive data.
- **Commercial Focus**: U.S. partnership discussions intensifying; European launch via Advanced Pharma.
- **Market Opportunity**: 1.5M high-risk U.S. surgeries addressable; $600/vial pricing under evaluation.
- **FDA Readiness**: Mock inspections and CMC module finalization underway for regulatory compliance.

**【CEO Summary Section】**
- **SHIELD 2 Phase 3 Trial Completion**: Enrollment of 800 patients achieved, with DSMB recommendation to conclude trial early due to positive efficacy signals. Top-line data expected by end of June 2025.
- **Regulatory Pathway**: NDA submission in Q1 2026 with Fast Track and Breakthrough Therapy designations; MAA submission in EU to follow.
- **Financial Position**: $15M December 2024 financing extends cash runway to Q3 2025. Additional $27M potential from warrant exercise post-positive data.
- **Commercial Strategy**: U.S. partnership prioritized for D-PLEX100 launch; European partner Advanced Pharma advancing pre-launch activities.

**【COO Market Update】**
- **U.S. Market Potential**: 12M annual surgeries addressable, with 1.5M high-risk procedures identified (e.g., exploratory laparotomy, cystectomy). IQVIA data supports $600/vial pricing assumption (2.5 vials avg. per procedure).
- **Surgeon Engagement**: Four new surgical specialties (general, hepato-pancreatobiliary, urology, oncogynecology) expressing interest in D-PLEX100 post-SSI reduction.
- **Partnership Momentum**: Advanced discussions with multiple U.S. partners; European MAA submission planned post-NDA.

**【CFO Financial Highlights】**
- **Cash Balance**: $8M as of Q1 2025, sufficient for operations through Q3 2025.
- **R&D Expenses**: $6.1M (vs. $5.1M YoY), driven by SHIELD 2 trial costs.
- **Net Loss**: $8.3M (vs. $6.4M YoY), reflecting increased R&D and G&A investments.

**【Q&A Key Takeaways】**
- **Pricing Strategy**: $600/vial tentative, to be finalized post-top-line data with partner input.
- **Data Disclosure**: Primary endpoint (SSI, mortality, re-intervention) and key secondary endpoints (SSI alone) to be reported. No smaller incision data included in primary analysis.
- **FDA Inspection Prep**: Mock audits and ex-FDA consultants engaged; CMC module nearing finalization.
- **Manufacturing Capacity**: Facility scaled for first 4-5 years of launch; expansion plans to follow demand assessment.

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

- **SHIELD II Milestone**: Early trial conclusion at 800 patients, signaling D-PLEX100's efficacy in preventing surgical site infections.
- **Financial Strength**: $14.5M financing extends cash runway, with $27M potential from warrant exercises post-results.
- **Market Opportunity**: 12M annual U.S. surgeries at risk of SSI, driven by rising post-COVID infection rates.
- **Strategic Focus**: Accelerate NDA prep, partner for U.S. commercialization, and expand platform into oncology via STING agonist collaboration.

**【CEO Opening Remarks】**
- SHIELD II Phase 3 trial for D-PLEX100 achieved 800 patient enrollment, meeting DSMB's recommendation to conclude trial early due to positive efficacy signals.
- Private placement financing of $14.5M extends cash runway into Q3 2025, with potential $27M from warrant exercises post-topline results.
- Anticipated top-line results in Q2 2025, with NDA submission targeting Fast Track and Breakthrough Therapy designations.

**【COO Market & Partnerships】**
- U.S. addressable market for D-PLEX100: ~12M surgeries annually (4.4M abdominal, 2.1M gynecology/urology).
- SSI costs $3.3B annually, with 75% of SSI-related deaths directly attributable to infections.
- Active partner discussions for U.S. commercialization post-NDA, with Europe covered by Advanced Pharma.
- Collaboration with ImmunoGenesis to enhance STING agonist efficacy via controlled drug delivery.

**【CFO Financial Highlights】**
- Cash balance of $15.6M as of Q4 2024, supporting operations into Q3 2025.
- R&D expenses: $7M (Q4 2024) vs. $4.6M (Q4 2023), driven by SHIELD II trial costs.
- Net loss: $8.5M (Q4 2024) vs. $6.4M (Q4 2023); full-year loss: $29M vs. $23.9M.
- Warrant exercises could provide $27M post-NDA approval, enhancing capital flexibility.

**【Q&A Key Takeaways】**
- Label expectations: Initial focus on abdominal surgeries, expanding based on data and partner input.
- Partner criteria: Hospital surgery suite presence, salesforce scale, and surgical infection expertise.
- Manufacturing control: Full commercial-stage GMP readiness, with FDA inspection planned post-NDA.
- Platform potential: Reformulating approved drugs (e.g., chemotherapy, growth factors) for new indications.
- ImmunoGenesis collaboration: Prolonged STING agonist delivery to enhance tumor immune response, with checkpoint inhibitor combinations under evaluation.

Actual	-7.59	-10.5	-12.3	-14.1	-16.8	-15.9	-21.3	-18.9	-18.3	-14.4	-9.6	-8.4	-3.9	-3.4	-3.97	-1.37	-1.25	-1.22	-1.13	-0.7	-0.78	-0.37	-0.41
Forecast	-11.025	-11.85	-15.225	-15	-16.2	-18.66	-16.87	-19.2	-18.55	-16.2	-12.36	-7.79	-9.21	-4.16	-3.5833	-1.4133	-1.3	-1.0025	-0.924	-0.82	-0.5475	-0.5225	-0.33
Surprise	+31.16%	+11.39%	+19.21%	+6.00%	-3.70%	+14.79%	-26.26%	+1.56%	+1.35%	+11.11%	+22.33%	-7.83%	+57.65%	+18.27%	-10.79%	+3.06%	+3.85%	-21.70%	-22.29%	+14.63%	-42.47%	+29.19%	-24.24%

Actual	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	--	--	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

PYPD

PYPD fundamentals

PYPD Q4 2025 Earnings

Earnings Call

You can ask Aime

PYPD

PYPD fundamentals

PYPD Q4 2025 Earnings

Earnings Call

PYPD Earnings Call Summary for Q4/20258:30 AM on Feb 11, 2026

PYPD Earnings Call Summary for Q3/20258:00 AM on Nov 12, 2025

PYPD Earnings Call Summary for Q2/20258:30 AM on Aug 13, 2025

PYPD Earnings Call Summary for Q1/20258:30 AM on May 14, 2025

PYPD Earnings Call Summary for Q4/20248:30 AM on Feb 12, 2025

You can ask Aime